

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners X, LLC</u> (Last) (First) (Middle) <u>8755 WEST HIGGINS ROAD, SUITE 1025</u> (Street) <u>CHICAGO IL 60631</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Verve Therapeutics, Inc. [VERV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/21/2021</u>	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.001	06/21/2021		C		1,254,404	A	(4)	1,254,404	I ⁽¹⁾⁽³⁾	ARCH Venture Fund X, L.P.
Common Stock, par value \$0.001	06/21/2021		C		1,254,405	A	(4)	1,254,405	I ⁽²⁾⁽³⁾	ARCH Venture Fund X Coverage, L.P.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Convertible Preferred Stock	(4)	06/21/2021		C ⁽⁴⁾		7,107,024		(4)	(5)	Common Stock	767,538	(4)	0	I	See Footnotes ⁽¹⁾⁽³⁾
Series A Convertible Preferred Stock	(4)	06/21/2021		C ⁽⁴⁾		7,107,023		(4)	(5)	Common Stock	767,538	(4)	0	I	See Footnotes ⁽²⁾⁽³⁾
Series A-2 Convertible Preferred Stock	(4)	06/21/2021		C ⁽⁴⁾		4,508,144		(4)	(5)	Common Stock	486,866	(4)	0	I	See Footnotes ⁽¹⁾⁽³⁾
Series A-2 Convertible Preferred Stock	(4)	06/21/2021		C ⁽⁴⁾		4,508,146		(4)	(5)	Common Stock	486,867	(4)	0	I	See Footnotes ⁽²⁾⁽³⁾

1. Name and Address of Reporting Person*
ARCH Venture Partners X, LLC

 (Last) (First) (Middle)
8755 WEST HIGGINS ROAD, SUITE 1025

 (Street)
CHICAGO IL 60631

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ARCH Venture Fund X, L.P.

 (Last) (First) (Middle)
8755 WEST HIGGINS ROAD, SUITE 1025

 (Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund X Overage, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners X, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners X Overage, L.P.](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[CRANDELL KEITH](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[NELSEN ROBERT](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Burow Kristina](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[GILLIS STEVEN](#)

(Last) (First) (Middle)

8755 WEST HIGGINS ROAD, SUITE 1025

(Street)		
CHICAGO	IL	60631
(City)	(State)	(Zip)

Explanation of Responses:

1. Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
2. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
3. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Robert Nelsen, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively. AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
4. The shares of Issuer's Preferred Stock converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-9.2595 basis immediately prior to the consummation of Issuer's initial public offering.
5. The expiration date is not relevant to the conversion of these securities.

Remarks:

/s/ ARCH Venture Fund X, L.P.,
By: ARCH Venture Partners X,
L.P., its General Partner, By: 06/23/2021
ARCH Venture Partners X, LLC,
its General Partner, By: Mark
McDonnell, attorney in-fact
/s/ ARCH Venture Fund X
Overage, L.P., By: ARCH
Venture Partners X Overage,
L.P., its General Partner, By: 06/23/2021
ARCH Venture Partners X, LLC,
its General Partner, By: Mark
McDonnell, attorney in-fact
/s/ ARCH Venture Partners X,
L.P., By: ARCH Venture
Partners X, LLC, its General 06/23/2021
Partner, By: Mark McDonnell,
attorney in-fact
/s/ ARCH Venture Partners X
Overage, L.P., By: ARCH
Venture Partners X, LLC, its 06/23/2021
General Partner, By: Mark
McDonnell, attorney in-fact
/s/ ARCH Venture Partners X,
LLC, By: Mark McDonnell, 06/23/2021
attorney in-fact
/s/ Keith Crandell, By: Mark 06/23/2021
McDonnell, attorney in-fact
/s/ Robert Nelsen, By: Mark 06/23/2021
McDonnell, attorney in-fact
/s/ Kristina Burow, By: Mark 06/23/2021
McDonnell, attorney in-fact
/s/ Steven Gillis, By: Mark 06/23/2021
McDonnell, attorney in-fact
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.